Results for this period
First quarter1 March 2026 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company opened 34 new stores, closed 12 stores, and renovated 55 stores. It expanded sales of private-label products, conducted promotions based on purchasing data, expanded and renovated dispensing rooms and waiting rooms, strengthened cooperation with medical institutions, increased efforts to acquire prescriptions, and optimized staffing. Net income declined due to the reversal of the impact of the additional deferred tax asset recognized in the same period of the previous year.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2026 to 31 May 2026 |
| Net Sales | 270,175 Millions of yen (YoY +10.1%) |
| Operating profit | 12,209 Millions of yen (YoY +10.9%) |
| Ordinary income | 11,588 Millions of yen (YoY +1.9%) |
| Profit attributable to owners of the parent | 6,901 Millions of yen (YoY -67.5%) |
| Net income per share | ¥38.14 |
| Equity ratio | End of the current fiscal period 46.0% / End of previous period 47.3% |
| Total assets | 638,463 Millions of yen |
| Net assets | 293,932 Millions of yen |
| Full-year earnings forecast | Net Sales 1,092,000 Millions of yen (YoY +8.1%) / Operating profit 54,000 Millions of yen (YoY +11.2%) / Ordinary income 55,000 Millions of yen (YoY +9.9%) / Net income 32,800 Millions of yen (YoY -27.1%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥35 → — (¥35.00 before the stock split)（0.0% (before the stock split)） |
| Depreciation and amortization | 4,234 Millions of yen |
| Impairment loss | 14 Millions of yen |
| Breakdown of extraordinary income (loss) | Impairment Losses 14 Millions of yen, Impairment loss on investment securities 424 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | At a board meeting held on 9 July 2026, the company resolved to issue 5,082,000 common shares through a third-party allotment to GIC Private Limited as the intended allottee. The payment date is 27 July 2026, and the amount to be raised is ¥16,008,439,600. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 189,992,514 |
| Treasury Shares at Period-End | 9,019,740 |
| Factors Behind Changes in Business Performance | The company opened 34 new stores, closed 12 stores, and renovated 55 stores. It expanded sales of private-label products, conducted promotions based on purchasing data, expanded and renovated dispensing rooms and waiting rooms, strengthened cooperation with medical institutions, increased efforts to acquire prescriptions, and optimized staffing. Net income declined due to the reversal of the impact of the additional deferred tax asset recognized in the same period of the previous year. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company opened new stores, renovated existing stores, expanded sales of private-label products, conducted promotions based on purchasing data, and strengthened efforts to acquire prescriptions in the dispensing pharmacy business. The decline in net income reflected the reversal of the impact of an additional deferred tax asset recognized in the same period of the previous year in connection with the absorption-type merger of the former I&H Co., Ltd.